SCHEMBL25754702

SCHEMBL25754702

c1ccc2c(c1)CN(c1ccc3c(c1)NCO3)S2

nearest known ligand 0.32

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.32
KMT2A Q03164 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32
NR3C2 P08235 1/20 0.32
OXTR P30559 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29406937 0.70 NPC1 (0.38) ALDH1A1KMT2ASMN1; SMN2
SCHEMBL19155132 0.70 NPC1 (0.38) ALDH1A1KMT2ASMN1; SMN2
SCHEMBL30918019 0.68 CASP6 (0.42) ALDH1A1KMT2ASMN1; SMN2
SCHEMBL27910653 0.65 DRD2 (0.39) ALDH1A1KMT2A
SCHEMBL8470138 0.63 KDM4E (0.52) ALDH1A1KMT2ASMN1; SMN2
SCHEMBL335978 0.62
SCHEMBL27872 0.62
SCHEMBL8469505 0.60 MAPT (0.42) ALDH1A1
SCHEMBL9327588 0.60 GAA (0.38) ALDH1A1KMT2ANPSR1OXTR
SCHEMBL2717534 0.60 MAPT (0.41) ALDH1A1KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023134647-A1 PIPERAZINO RING-CONTAINING DERIVATIVE, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF 优领医药科技(香港)有限公司 2023-07-20 WO disclosed
WO-2023116865-A1 PYRAZOLE-CONTAINING DERIVATIVE, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF 优领医药科技(上海)有限公司 2023-06-29 WO disclosed
WO-2023072096-A1 TETRAHYDROFURAN-CONTAINING POLYCYCLIC DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF 优领医药科技(香港)有限公司 2023-05-04 WO disclosed